The RCMI Center for Cancer Research established through NIH/NIMHD's RCMI program will continue to be a critical support mechanism in driving Xavier's efforts to enhance and expand its biomedical research capabilities. As stated in Section 1, the primary goal of the RCMI is to enhance faculty and programmatic research competitiveness, especially as related to the areas of cancer, minority health disparities and translational research. The Administrative Core will achieve this goal through the following aims:
Aim 1. To provide effective leadership in governing, monitoring and guiding the key activities of the RCMI program;
Aim 2. To provide user-friendly assistance in developing successful proposals for external support and to patent and license intellectual property;
Aim 3. To engage in strategic planning for ongoing development of the RCMI program and coordinate the effort with the University's strategic planning process.
Aim 4. To promote and facilitate the development of a cohesive group of faculty committed to being actively engaged in health disparities and translational research. The Administrative Core will consist of two Pis: Dr. Gene D'Amour and Dr. Guangdi Wang. Dr. Wang will also serve as the Program Director. In addition, there will be two Associate PDs, a Program Advisor/Consultant, and a Program Manager. The Administrative Core members will meet monthly with the Activity Leaders including the Core Directors and Co-Directors to review progress, identify problems, discuss and implement solutions and improvement plans to ensure that each specific aim is achieved as measured by assessment milestones.

Agency
National Institute of Health (NIH)
Institute
National Institute on Minority Health and Health Disparities (NIMHD)
Type
Research Centers in Minority Institutions Award (G12)
Project #
5G12MD007595-07
Application #
8933971
Study Section
Special Emphasis Panel (ZMD1-MLS)
Project Start
2015-04-01
Project End
2019-03-31
Budget Start
2015-04-01
Budget End
2016-03-31
Support Year
7
Fiscal Year
2015
Total Cost
$1,098,827
Indirect Cost
$266,526
Name
Xavier University of Louisiana
Department
Type
DUNS #
020857876
City
New Orleans
State
LA
Country
United States
Zip Code
70125
Aqeel, Salem M; Huang, Zhongyuan; Walton, Jonathan et al. (2018) Polyvinylidene Fluoride (PVDF)/Polyacrylonitrile (PAN)/Carbon Nanotube Nanocomposites for Energy Storage and Conversion. Adv Compos Hybrid Mater 1:185-192
Zheng, Shilong; Guo, Shanchun; Zhong, Qiu et al. (2018) Biocompatible Boron-Containing Prodrugs of Belinostat for the Potential Treatment of Solid Tumors. ACS Med Chem Lett 9:149-154
Dai, Lu; Smith, Charles D; Foroozesh, Maryam et al. (2018) The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo. Int J Cancer 142:2153-2162
Drennen, Callie; Gorse, Erin; Stratford Jr, Robert E (2018) Cellular Pharmacokinetic Model-Based Analysis of Genistein, Glyceollin, and MK-571 Effects on 5 (and 6)-Carboxy-2',7'-Dichloroflourescein Disposition in Caco-2 Cells. J Pharm Sci 107:1194-1203
Zhang, Wensheng; Flemington, Erik K; Zhang, Kun (2018) Driver gene mutations based clustering of tumors: methods and applications. Bioinformatics 34:i404-i411
Li, Xiang; Zhang, Changde; Guo, Shanchun et al. (2018) Structure-activity relationship and pharmacokinetic studies of 3-O-substitutedflavonols as anti-prostate cancer agents. Eur J Med Chem 157:978-993
Patanapongpibul, Manee; Zhang, Changde; Chen, Guanglin et al. (2018) Optimization of diarylpentadienones as chemotherapeutics for prostate cancer. Bioorg Med Chem 26:4751-4760
Thomas-Porch, Caasy; Li, Jie; Zanata, Fabiana et al. (2018) Comparative proteomic analyses of human adipose extracellular matrices decellularized using alternative procedures. J Biomed Mater Res A 106:2481-2493
Chen, Guobao; Bracamonte-Baran, William; Diny, Nicola L et al. (2018) Sca-1+ cardiac fibroblasts promote development of heart failure. Eur J Immunol 48:1522-1538
Fang, Ziling; Cao, Bo; Liao, Jun-Ming et al. (2018) SPIN1 promotes tumorigenesis by blocking the uL18 (universal large ribosomal subunit protein 18)-MDM2-p53 pathway in human cancer. Elife 7:

Showing the most recent 10 out of 244 publications